1 ABSTRACT
Background Adults ≥65 years of age are at increased risk for atypical presentations of chikungunya disease as well as severe outcomes including death.
Methods A phase 3, randomized, double-blind, placebo-controlled, parallel-group trial was conducted in adults ≥65 years of age where participants received a single intramuscular dose of chikungunya virus (CHIKV) virus-like particle (VLP) vaccine or placebo on Day 1. Baseline and postvaccination CHIKV serum neutralizing antibody (SNA) titers (NT80) were assessed at selected timepoints. Safety was assessed through Day 183.
Results A total of 413 participants (206 vaccine, 207 placebo) were randomized. Coprimary endpoints were met including 1) immunologic superiority of CHIKV SNA titers compared to placebo and 2) by geometric mean titer at Day 22. CHIKV VLP vaccine induced a protective seroresponse (SNA NT80 ≥100; considered the presumptive seroprotective antibody response), in 82% of individuals at Day 15, in 87% of individuals at Day 22, and in 76% of individuals at Day 183. There were no notable differences in AE rates between groups and most AEs were grade 1 or 2 in severity. No vaccine-related serious adverse events or deaths occurred.
Conclusions We provide robust data from adults ≥65 years of age demonstrating that CHIKV VLP vaccine has a favorable safety profile and can provide a high rate of protection within 2 weeks postvaccination and through 6 months of follow-up. (Funded by Emergent BioSolutions Inc. and Bavarian Nordic A/S [as successor in interest to Emergent BioSolutions Inc.]; ClinicalTrials.gov number, NCT05349617).
Competing Interest Statement
All authors are current or previous employees/contractors of Bavarian Nordic and/or Emergent BioSolutions.
Clinical Trial
NCT05349617
Funding Statement
This study was funded by Emergent BioSolutions Inc. and Bavarian Nordic A/S [as successor in interest to Emergent BioSolutions Inc.]
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
WCG (Western-Copernicus Group) Institutional Review Board gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* A complete list of the EBSI-CV-317-005 Study Group is provided in the Supplementary Appendix.
Table 2 was revised with the correct "N" in the column header.
Data Availability
De-identified data produced in the present study are available upon reasonable request to the authors.
